Gainers

• Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million.
• NeuroSense Therapeutics (NASDAQ:NRSN) shares increased by 5.57% to $0.4. The company's market cap stands at $13.5 million.
• Marker Therapeutics (NASDAQ:MRKR) shares moved upwards by 5.26% to $1.6. The company's market cap stands at $25.0 million.
• Vivos Therapeutics (NASDAQ:VVOS) stock rose 4.78% to $0.28. The market value of their outstanding shares is at $5.5 million.
• DocGo (NASDAQ:DCGO) shares increased by 4.6% to $0.4. The market value of their outstanding shares is at $37.7 million.
• Nautilus Biotechnology (NASDAQ:NAUT) shares increased by 4.39% to $0.92. The market value of their outstanding shares is at $111.3 million.

Losers

• Akanda (NASDAQ:AKAN) shares fell 14.2% to $4.25 during Tuesday's after-market session. The company's market cap stands at $2.0 million.
• Spyre Therapeutics (NASDAQ:SYRE) shares declined by 11.81% to $94.69. The company's market cap stands at $9.1 billion.
• Biodexa Pharmaceuticals (NASDAQ:BDRX) shares decreased by 10.17% to $1.06. The company's market cap stands at $1.2 million.
• Kestra Medical Techs (NASDAQ:KMTS) stock decreased by 9.74% to $24.3. The market value of their outstanding shares is at $1.5 billion.
• Profusa (NASDAQ:PFSA) stock decreased by 7.21% to $4.64. The company's market cap stands at $2.7 million. As per the press release, Q2 earnings came out 3 days ago.
• Senti Biosciences (NASDAQ:SNTI) shares decreased by 7.03% to $0.36. The company's market cap stands at $11.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.